Embedded Files
Note - There is no evidence here of this fictional person that is claimed to factually apply to any other actual or imagined person by the same last name. This is only a collection of references to a name, nothing more. This is public information. No claims are made here, this is just information.
2010 - International AIDS Society Conference Evaluation Report
2010 - International AIDS Society Conference Evaluation Report
See page 06 : "Virginia Benassi - Masters in Peace-building and Conflict Resolution at the University of Trento School of International Studies, Trento, Italy, and Intern, International AIDS Society, Geneva, Switzerland"
2011 - International AIDS Society:
2011 - International AIDS Society:
"The author of this report is Laetitia Lienart, the Planning, Monitoring and Evaluation expert at the IAS Secretariat who conducted the members’ survey. Sincere thanks are extended to the 1,882 IAS members who completed the 2011 IAS Members’ Survey. As a result of their participation, the IAS is well positioned to identify areas for improvement. A number of people were involved in the development of the survey and their contribution is gratefully acknowledged, in particular: • Erika Lundstrom, Virginia Gomez, Sian Bowen, Shirin Heidari, Mirjam Eckert, Virginia Benassi and Bernard Kadasia, from the IAS Secretariat. • The IAS Governing Council members. Thanks are also extended to Glenn O’Neil, evaluation consultant and founder of Owl RE, for his contribution to qualitative analysis, and to Janette Bennett, consultant, for the editing of the report"
https://www.iasociety.org/Web/WebContent/File/2011_IAS_Membership_Survey.pdf
2011-international-aids-society-membership-survey.pdf
https://drive.google.com/file/d/1yiSaRUHLN0cC4aGseCZRao-lwwxC7fN3/view?usp=sharing
2011-international-aids-society-membership-survey-img-pg-cover
2011-international-aids-society-membership-survey-img-pg-6-vb
2011-international-aids-society-membership-survey-img-pg-8
2011-international-aids-society-membership-survey-img-pg-12
2012 - "IAS HQ 2012 ORG CHART - International AIDS Society"
2012 - "IAS HQ 2012 ORG CHART - International AIDS Society"
Society Website : www.iasociety.org
IAS HQ 2012 ORG CHART - International AIDS Society / Saved PDF : [HI0073][GDrive]
2012 (April) - Now ISET Assistant, working for Jelena MIlovic
2012 (April) - Now ISET Assistant, working for Jelena MIlovic
https://www.yumpu.com/en/document/view/21820574/ias-hq-2012-org-chart-international-aids-society
2013 (July 15) - The Pantagraph (Bloomington, IL) : A "Virginia Benassi" of Brazil, a "visiting schoolteacher" ?
2013 (July 15) - The Pantagraph (Bloomington, IL) : A "Virginia Benassi" of Brazil, a "visiting schoolteacher" ?
2015 (Feb 24-26) - W.H.O : "SUMMARY REPORT: First Workshop of the Partners Group on Ebola Vaccines Deployment"
2015 (Feb 24-26) - W.H.O : "SUMMARY REPORT: First Workshop of the Partners Group on Ebola Vaccines Deployment"
First find of Virginia Benassi on a W.H.O doc
First find of Virginia Benassi on a W.H.O doc
https://apps.who.int/iris/rest/bitstreams/713925/retrieve
WHO_EVD_Meet_HIS_15.2_eng.pdf
24-26 February 2015, Geneva, Switzerland
Rev. 1
2016 (May) - W.H.O : EBOLA STRATEGY
2016 (May) - W.H.O : EBOLA STRATEGY
Global Ebola Vaccine
Implementation Team (GEVIT)
Practical guidance on the use of
Ebola vaccine in an outbreak response
Draft Guidance, May 2016
https://www.who.int/csr/resources/publications/ebola/gevit_guidance_may2016.pdf
2016-05-world-health-organization-global-ebola-vaccine-implementation-team-practical-guidance-in-outbreak-draft.pdf
WHO/Headquarters: Madhava Balakrishnan, Virginia Benassi, Alison Brunier, Alejandro Costa, Martine Denis, Bernardus Ganter, Ana Maria Henao-Restrepo, Barbara Jauregui, Souleymane Kone, Jacqueline Lee-Endt, Christine Maure, Elisabeth Pluut, Marie-Pierre Preziosi, Lisa Stockdale and James Stuart.
2016 (August) - World Health Organization - "WHO Research and Development : Blueprint Evaluation of ideas for potential platforms to support development and production of health technologies for priority infectious diseases with epidemic potential August 2016"
2016 (August) - World Health Organization - "WHO Research and Development : Blueprint Evaluation of ideas for potential platforms to support development and production of health technologies for priority infectious diseases with epidemic potential August 2016"
Saved PDF : [HI007J][GDrive] / Dates: created Aug 16 2016 (and updated in 2018 ) - 1,607,709 bytes
Image of page 17 of PDF : [HI007S][GDrive]
Accelerated Defense against Emerging Pathogen Threats (ADEPT)
Lead Institution: The Geneva Foundation
Participating Institutions: US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Dr Gustavo Palacios, Director of the Center for Genomic Sciences (CGS), US Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, US. [presentation available electronically]
The Geneva Foundation together with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) proposed to create the Accelerated Defense against Emerging Pathogen Threats (ADEPT) platform, which is designed to provide a logical and effective plan for developing MCMs for both known and novel threats.
ADEPT is an “R&D toolbox” comprised of parallel programs that will converge to generate candidate MCMs ready for clinical trials within 12 months of implementation. The ADEPT platform would be fully integrated and completely open access, in order to maximize resources and expedite research while assuring that the data generated is available in real time to the entire research community.
The ADEPT platform would encompass numerous approaches and technologies that can be quickly adapted to generate candidate products in sufficient quantities to enable use in outbreak conditions. The modular framework of ADEPT could be immediately applied to known agents, including emerging diseases likely to cause major epidemics, such as those identified by WHO, for which some of the knowledge gaps are already filled. Importantly, ADEPT could be maintained in “standby” mode, where only table-top and wet-lab exercises are performed until WHO becomes concerned with an outbreak situation and activate the ADEPT platform. Such exercises would not only ensure the readiness of ADEPT for responding to known agents, but would also establish roadmaps that could be applied to the development of MCMs for future unknown pathogens.
The cost of ADEPT in “standby” mode is anticipated to be ~$3m per annum; while the cost of the activation mode would depend on the type of outbreak involved: a worst case scenario of an outbreak including a completely uncharacterized novel agent is anticipated to be ~$30m per annum.
Although ADEPT is focused on viral pathogens, it would be possible to adapt this model for other types of pathogens if needed. The key parallel R&D components within ADEPT are: identifying and characterizing the known or novel pathogen; developing a suitable animal model to assess MCMs; determining gene sequences for use in molecular vaccine technologies; providing an isolate of the pathogen for testing MCMs; developing and validating tailored molecular and serological diagnostic tools; activating a biopharmaceutical approach to identify small molecule therapeutic candidates; characterizing the immune B cell repertoire from survivors and resistant individuals for immune therapy or prophylaxis; and, obtaining clinical bio-samples to facilitate plasmapheresis and future human clinical trials.
With Sina A Bavari (born 1959) ...
Accelerated Defence against Emerging Pathogen Threats (ADEPT) Sina Bavari, Louise Pitt, Gustavo Palacios, Connie Schmaljohn (USAMRIID, USA)
Proponents United States Army Research Institute for Infectious Diseases (USAMRIID) Sina Bavari Chief of Immunology, Target Identification, and Translational Research USAMRIID Fort Detrick, Maryland, United States (USA)
"Accelerated Defense against Emerging Pathogen Threats"
May 2017
https://www.eurekalert.org/news-releases/750561
USAMRIID and its partners have proposed to develop a platform called Accelerated Defense against Emerging Pathogen Threats (ADEPT) to provide a logical and effective plan for rapidly developing medical countermeasures.
"The ADEPT platform was designed with a clear goal -- to quickly generate the information and medical countermeasures needed to stop an epidemic," Palacios said. "It provides a strong foundation with multiple parallel research and development efforts under one organizational structure."
In addition, he said, ADEPT is not based on a specific type of medical countermeasure, but rather on the generation of information that will result in the development of the most appropriate product for any emerging disease outbreak. At the same time, it is vital that the information collected and generated by ADEPT is immediately available to the entire scientific community involved in the outbreak response. Consequently, ADEPT is completely open access and data will be shared in real time with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and the affected nations.
Learn more about USARMRIID ADEPT :
NOT TO BE CONFUSED WITH DARPA'S ADEPT :
2018 - "A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease Short Title: 2018 Ebola MCM RCT Protocol"
2018 - "A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease Short Title: 2018 Ebola MCM RCT Protocol"
https://clinicaltrials.gov/ProvidedDocs/86/NCT03719586/Prot_SAP_ICF_000.pdf
2019-10-usa-niaid-office-of-clinical-research-policy-and-regulatory-operations-2018-ebola-mcm-rct-protocol.pdf
2018-
Sponsored by: Office of Clinical Research Policy and Regulatory Operations (OCRPRO) National Institute of Allergy and Infectious Diseases 5601 Fishers Lane Bethesda, MD 20892 NIH Protocol Number: 19-I-0003 Protocol IND #: 125530 ClinicalTrials.gov Number: NCT03719586 Date: 4 October 2019 Version: 7.0
2018
2018
https://www.finddx.org/wp-content/uploads/2018/10/ASTMH2018_Dx-landscape_FINAL.pdf
ASTMH2018_Dx-landscape_FINAL.podf
2019 Draft Wellcome Epidemics Evaluation - RFP Document
2019 Draft Wellcome Epidemics Evaluation - RFP Document
https://wellcome.org/sites/default/files/wellcome-rfp-2019-evaluation-supportive-care-epidemics.pdf
wellcome-rfp-2019-evaluation-supportive-care-epidemics.pdf
Epidemics SCG (ESCG) panel
▪ Dr. Josie Golding – Programme Manager, Epidemics (Wellcome)
▪ Dr. Peter Hart – Project Officer, Epidemics (Wellcome)
▪ Dr. Cathy Roth – Senior research fellow, Department for International Development (UK Government)
Dr. Marie-pierre Preziosi – R&D Blueprint co-lead (WHO)
Dr. Gail Carson – Chair, Research Subgroup (GOARN)
Dr. Virginia Benassi – R&D Blueprint technical officer (WHO)
Dr.JanetDiaz–TeamLead,ClinicalManagement,HealthEmergencyProgramme(WHO)
Dr. Ismaila Mamane Sani – Ministry of Health, Republic of Niger
2020 (March 13) - W.H.O. :
2020 (March 13) - W.H.O. :
2020-03-13-informal-consultation-on-the-potential-role-of-chloroquine-in-the-clinical-management-of-covid-19-infection517535f6d96e4b9f8faef91a49e4e3db.pdf
2020-03-13-informal-consultation-on-the-potential-role-of-chloroquine-in-the-clinical-management-of-covid-19-infection517535f6d96e4b9f8faef91a49e4e3db-img-cvr
2020-03-13-informal-consultation-on-the-potential-role-of-chloroquine-in-the-clinical-management-of-covid-19-infection517535f6d96e4b9f8faef91a49e4e3db-img-pg-03
2020-03-13-informal-consultation-on-the-potential-role-of-chloroquine-in-the-clinical-management-of-covid-19-infection517535f6d96e4b9f8faef91a49e4e3db-img-pg-04
2020-03-13-informal-consultation-on-the-potential-role-of-chloroquine-in-the-clinical-management-of-covid-19-infection517535f6d96e4b9f8faef91a49e4e3db-img-pg-05
2020-03-13-informal-consultation-on-the-potential-role-of-chloroquine-in-the-clinical-management-of-covid-19-infection517535f6d96e4b9f8faef91a49e4e3db-img-pg-06
2020-03-13-informal-consultation-on-the-potential-role-of-chloroquine-in-the-clinical-management-of-covid-19-infection517535f6d96e4b9f8faef91a49e4e3db-img-pg-07
2020 (March 18) - W.H.O : ""
https://view.ckcest.cn/AllFiles/ZKBG/Pages/591/informal-consultation-on-the-role-of-therapeutics-in-covid-19-prophylaxis-and-post-exposure-prophylaxis.pdf
2020-03-18-who-informal-consultation-on-the-role-of-therapeutics-in-covid-19-prophylaxis-and-post-exposure-prophylaxis.pdf
https://www.who.int/docs/default-source/documents/r-d-blueprint-meetings/cchf-list-of-participants.pdf
2020 (Oct 05-07) : W.H.O : "Strategic Advisory Group of Experts (SAGE) on Immunization 5-7 October 2020"
2020 (Oct 05-07) : W.H.O : "Strategic Advisory Group of Experts (SAGE) on Immunization 5-7 October 2020"
Virtual meeting
Geneva, Switzerland
List of Participants
final-lop-sage-october-2020.pdf
Benassi, Ms Virginia
World Health Organization
2020 (Research) - "Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development
2020 (Research) - "Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development
Nathen E. Bopp, Jaclyn A. Kaiser, Ashley E. Strother, Alan D.T. Barrett, David W.C. Beasley, Virginia Benassi, Gregg N. Milligan, Marie Pierre Preziosi, Lisa M. Reece
Research output: Contribution to journal › Review article › peer-review
"
DOWNKOADED - 10.1038-s41541-020-00257-5.pdf
DOWNKOADED - 10.1038-s41541-020-00257-5.pdf
Access to Document
Access to Document
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a newly emergent tick-borne bunyavirus first discovered in 2009 in China. SFTSV is a growing public health problem that may become more prominent owing to multiple competent tick-vectors and the expansion of human populations in areas where the vectors are found. Although tick-vectors of SFTSV are found in a wide geographic area, SFTS cases have only been reported from China, South Korea, Vietnam, and Japan. Patients with SFTS often present with high fever, leukopenia, and thrombocytopenia, and in some cases, symptoms can progress to severe outcomes, including hemorrhagic disease. Reported SFTSV case fatality rates range from ~5 to >30% depending on the region surveyed, with more severe disease reported in older individuals. Currently, treatment options for this viral infection remain mostly supportive as there are no licensed vaccines available and research is in the discovery stage. Animal models for SFTSV appear to recapitulate many facets of human disease, although none of the models mirror all clinical manifestations. There are insufficient data available on basic immunologic responses, the immune correlate(s) of protection, and the determinants of severe disease by SFTSV and related viruses. Many aspects of SFTSV virology and epidemiology are not fully understood, including a detailed understanding of the annual numbers of cases and the vertebrate host of the virus, so additional research on this disease is essential towards the development of vaccines and therapeutics.
Beasley Lab : https://researchexperts.utmb.edu/en/persons/david-beasley
Call for comments is now closed
Thank you to everyone who contributed to the Zika Virus Research and Development (R&D) Roadmap public review and comment period between 26 February through 16 April 2021. The roadmap development team appreciates the time and thought everyone gave to their comments. The roadmap is now being updated based on the feedback received.
The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, the University of Texas Medical Branch (UTMB), an expert team of taskforce members from around the world, and the World Health Organization (WHO) have developed a draft Zika virus (ZIKV) Research and Development (R&D) Roadmap. The roadmap is a key component of the WHO’s R&D Blueprint, a global strategy and preparedness plan that allows the activation of R&D activities in advance of and during epidemics.
The purpose of the roadmap is to accelerate the development and implementation of effective medical countermeasures for ZIKV aimed at reducing morbidity, mortality, and transmission. The roadmap identifies the vision, strategic goals, and aligned milestones aimed at developing effective diagnostics, therapeutic agents, and vaccines for ZIKV.
Please provide comments following the instructions below. Kindly note that you can either provide input on the entire document or only on certain parts. Comments may be publicly disclosed at a later stage of the review process; submission of comments will be considered as permission to publicly disclose feedback received. Comments should be submitted in English. Input received from this consultation will contribute to the further development and finalization of the roadmap.
Instructions for providing comments:
The draft roadmap has line numbers to help align comments with specific sections.
Submit your comments on the draft roadmap using this online form.
The online form has three sections:
Section 1: Your contact information. This is to document participation in the review process and to enable us to reach you if we need clarification on your comments.
Section 2: General comments on the draft roadmap. There are 2 general questions (optional) about the draft roadmap. If you have no further comments, you can confirm that you have read the roadmap and have no additional feedback (you can complete the review by selecting “no” when prompted in this section).
You will not be able to revise your responses to Section 1 or Section 2 once you move on to Section 3.
Section 3: Section-specific review. You will have the opportunity to comment on each of the 5 topic-specific sections of the draft roadmap. A table of contents is available to facilitate your review of the sections. You may select individual sections for comment.
If you are commenting on a specific part of the roadmap please include the line number(s) for reference.
Please submit comments no later than Friday, 16 April 202.
If you have questions on the roadmap or public comment period, please email Ms. Virginia Benassi (benassiv@who.int) with the subject line “Zika virus R&D Roadmap.”
2021 (April)
2021 (April)
https://www.paho.org/sites/default/files/usa-400_eng.pdf
2021-04-pan-american-health-organization-who-collaboration-webinat-usa-400-eng.pdf
USA-400
PAHO/WHO Collaborating Centre for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases
Authors: Alan DT Barrett, PhD; David WC Beasley, PhD; and Gregg N Milligan, PhD
Department/Division, Institution: Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA
Recently, in collaboration with WHO, we are partnering to provide inputs to baseline situation analyses, TPPs and/or R&D roadmaps to be developed for specific priority pathogens as indicated by WHO. At present we are actively participating on the WHO Zika R&D Roadmap with Virginia Benassi, L.L.M. and Marie-Pierre Preziosi, M.D., Ph.D. (both with Initiative for Vaccine Research, WHO). This activity began in July 2019 and is co-directed as a partnership between members of the Zika Roadmap Steering Committee (SC) comprised of: the WHO R&D Blueprint Roadmaps team (Virginia Benassi and Marie-Pierre Preziosi), the UTMB CC (Alan Barrett, David Beasley, and Gregg Milligan); and the
University of Minnesota Center for Infectious Disease Research and Policy (Anje Mehr, Kristine Moore, Michael Osterholm, and Julie Ostrowsky).
Page updated
Report abuse